Treatment of New World cutaneous leishmaniasis with miltefosine

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 100, Issue SUPPL. 1, 2006, Pages

  Soto, J ^a   Berman, J ^b  

^a Consorcio de Investigaciones Bioclínicas ^*  (Colombia)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cutaneous leishmaniasis; Drug therapy; Leishmania panamensis; Miltefosine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLOPURINOL; ANTIMONY; ASPARTATE AMINOTRANSFERASE; CREATININE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PLACEBO;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLOMBIA; DATA ANALYSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; ENDEMIC DISEASE; GUATEMALA; HEADACHE; HUMAN; LEISHMANIA BRAZILIENSIS; LEISHMANIA MEXICANA; LEISHMANIA PANAMENSIS; LIVER DYSFUNCTION; MOTION SICKNESS; NAUSEA; NONHUMAN; PILOT STUDY; QUANTITATIVE ANALYSIS; SKIN CANCER; SKIN LEISHMANIASIS; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIPROTOZOAL AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; DRUG EVALUATION; HUMANS; LEISHMANIASIS, CUTANEOUS; MULTICENTER STUDIES; MULTICENTER STUDIES AS TOPIC; PHOSPHORYLCHOLINE; PILOT PROJECTS; TREATMENT OUTCOME;

LEISHMANIA PANAMENSIS;

EID: 33749336171     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2006.02.022     Document Type: Article

References (17)

1. Arana B.A., Navin T.R., Arana F.E., Berman J.D., and Rosenkainer F. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clin. Infect. Dis. 18 (1994) 381-384
2. Chico M.E., Guderian R.H., Cooper P.J., Armijos R., and Grogl M. Evaluation of a direct immunofluorescent antibody (DIFMA) test using Leishmania genus-specific monoclonal antibody in the routine diagnosis of cutaneous leishmaniasis. Rev. Soc. Bras. Med. Trop. 28 (1995) 99-103
3. Dummer R., Krasovec M., Roger J., Sindermann H., and Burg G. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. J. Am. Acad. Dermatol. 29 (1993) 963-970
4. Escobar P., Matu S., Marques C., and Croft S.L. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop. 81 (2002) 151-157
5. Herwaldt B.L., Arana B.A., and Navin T.R. The natural history of cutaneous leishmaniasis in Guatemala. J. Infect. Dis. 165 (1992) 518-527
6. Kreutzer R.D., Semko M.E., Hendricks L.D., and Wright N. Identification of Leishmania spp. by multiple isozyme analysis. Am. J. Trop. Med. Hyg. 32 (1983) 703-715
7. Navin T.R., Arana B.A., Arana F.E., de Merida A.M., Castillo A.L., and Pozuelos J.L. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am. J. Trop. Med. Hyg. 42 (1990) 43-50
8. Navin T.R., Arana B.A., Arana F.E., Berman J.D., and Chajon J.F. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J. Infect. Dis. 165 (1992) 528-534
9. Noyes H.A., Belli A.A., and Miangon R. Appraisal of various random amplified polymorphic DNA-polymerase chain-reaction primers for Leishmania identification. Am. J. Trop. Med. Hyg. 55 (1996) 98-105
10. Palacios R., Osorio L.E., Grajalew L.F., and Ochoa M.T. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am. J. Trop. Med. Hyg. 64 (2001) 187-193
11. Schmidt-Ott R., Klenner T., Overath P., and Aebischer T. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 93 (1999) 85-90
12. Smorenburg C.H., Seynaeve C., Bontenbal M., Planting A.S., Sindermann H., and Verweij J. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. Anticancer Drugs 11 (2000) 825-828
13. Soto J., Fuya P., Herrera R., and Berman J. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin. Infect. Dis. 26 (1998) 56-58
14. Soto J., Toledo J., Gutierrez P., Nicholls R.S., Padilla J., Engel J., Fischer C., Voss A., and Berman J. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 33 (2001) E57-E61
15. Soto J., Arana B.A., Toledo J., Rizzo N., Vega J.C., Diaz A., Luz M., Gutierrez P., Arboleda M., Berman J.D., Junge K., Engel J., and Sindermann H. Miltefosine for New World cutaneous leishmaniasis. Clin. Infect. Dis. 38 (2004) 1266-1272
16. Soto-Mancipe J., Grogl M., and Berman J.D. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin. Infect. Dis. 16 (1993) 417-425
17. Velez I., Agudelo S., Hendrickx E., Puerta J., Grogl M., Modabber F., and Berman J. Inefficacy of Allopurinol for Colombian cutaneous leishmaniasis: a randomized, controlled trial. Ann. Int. Med. 126 (1997) 232-236